Tempest Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Tempest Therapeutics

05/11/2022 03:07

* Tempest Therapeutics Inc  TPST.OQ   TPST.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 8 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Tempest
Therapeutics Inc
is for a loss of 80 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $10​, above​ its last closing price
of $1.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.93       -0.92      -0.79     Beat    14.4
 Mar. 31 2022  -1.12       -1.12      -1.18     Missed  -5.7
 Dec. 31 2021              -1.23      -1.12     Beat    9.1​
 Sep. 30 2021  -1.04       -1.05      -1.21     Missed  -15.6
 ​​Jun.        -0.87       -0.87      -7.63     Missed  -772
 30 2021                                                
 Mar. 31 2021              -5.25      -6.60     Missed  -25.7​
 Dec. 31 2020              -5.15      -5.85     Missed  -13.6
 Sep. 30 2020  -7.03       -6.90      -5.10     Beat    26.1
 This summary was machine generated November 5 at 03:06 GMT.  All
figures in US dollars  unless otherwise stated